Literature DB >> 19906099

What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers?

Barney S Graham1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19906099      PMCID： PMC2792820          DOI： 10.1111/j.1365-2249.2009.04055.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  9 in total

1.  Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Authors:  Nina D Russell; Barney S Graham; Michael C Keefer; M Juliana McElrath; Steve G Self; Kent J Weinhold; David C Montefiori; Guido Ferrari; Helen Horton; Georgia D Tomaras; Sanjay Gurunathan; Lynn Baglyos; Sharon E Frey; Mark J Mulligan; Clayton D Harro; Susan P Buchbinder; Lindsey R Baden; William A Blattner; Beryl A Koblin; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

Review 2.  25 years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines.

Authors:  E Scherer; D Douek; A McMichael
Journal:  Clin Exp Immunol       Date:  2008-08-29       Impact factor: 4.330

Review 3.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

4.  Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Jonathan R Lawson; Raman P Singh; Kimberli A Schmidt; Thomas Evans; Patricia Earl; Danielle Harvey; Genoveffa Franchini; James Tartaglia; David Montefiori; Shilpa Hattangadi; Bernard Moss; Marta L Marthas
Journal:  J Acquir Immune Defic Syndr       Date:  2005-02-01       Impact factor: 3.731

Review 5.  Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity.

Authors:  D R Kaufman; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

6.  Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Authors:  B S Graham; T J Matthews; R B Belshe; M L Clements; R Dolin; P F Wright; G J Gorse; D H Schwartz; M C Keefer; D P Bolognesi
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

7.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

9.  Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1.

Authors:  Richard E Haaland; Paulina A Hawkins; Jesus Salazar-Gonzalez; Amber Johnson; Amanda Tichacek; Etienne Karita; Olivier Manigart; Joseph Mulenga; Brandon F Keele; George M Shaw; Beatrice H Hahn; Susan A Allen; Cynthia A Derdeyn; Eric Hunter
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.